Katie Ellias

Director/Board Member at SAB BIOTHERAPEUTICS, INC.

47 year

Health Technology

Finance

Consumer Services

Profile

Katie Ellias currently works at SAB Biotherapeutics, Inc., as Independent Director from 2023.
Ms. Ellias also formerly worked at Capillary Biomedical LLC, as Director from 2019 to 2022, Endeavour Vision SA, as Investment Director from 2016 to 2017, A Breakthrough T1D Venture LLC, as Managing Director from 2018 to 2024, Veralox Therapeutics, Inc., as Director, I2o Therapeutics, Inc., as Director, DiogenX SAS, as Director, Sofinnova Partners SAS, as Principal from 2011 to 2016, and Tech Health Experts, as Consultant from 2017 to 2018.
Ms. Ellias received her undergraduate degree in 2000 from Yale University and Masters Business Admin degree in 2006 from The Wharton School of the University of Pennsylvania.

Katie Ellias active positions

Companies	Position	Start
SAB BIOTHERAPEUTICS, INC.	Director/Board Member	20/11/2023

All active positions of Katie Ellias

Former positions of Katie Ellias

Companies	Position	End
JDRF T1D Fund JDRF T1D Fund Investment ManagersFinance T1D Fund invests in companies located across the globe. The firm focuses on health technology sector. It participates in early stage capital requirements.	Private Equity Investor	01/11/2024
Capillary Biomedical LLC Capillary Biomedical LLC Medical SpecialtiesHealth Technology Develops medical devices for diabetes management	Director/Board Member	01/07/2022
Tech Health Experts Tech Health Experts Information Technology ServicesTechnology Services Provides technical support services	Consultant / Advisor	30/07/2018
Endeavour Vision SA Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired.	Private Equity Investor	30/09/2017
Sofinnova Partners SAS Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners invests in companies located in the United States, France and Europe. The firm targets companies operating in the fields of life sciences and technology sectors. It provides financing for seed and early stage capital requirements.	Private Equity Investor	30/11/2016

See the detail of Katie Ellias's experience

Training of Katie Ellias

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Katie Ellias's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	11
Capillary Biomedical LLC Capillary Biomedical LLC Medical SpecialtiesHealth Technology Develops medical devices for diabetes management	Health Technology
Sofinnova Partners SAS Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners invests in companies located in the United States, France and Europe. The firm targets companies operating in the fields of life sciences and technology sectors. It provides financing for seed and early stage capital requirements.	Finance
Yale University Yale University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Endeavour Vision SA Endeavour Vision SA Investment ManagersFinance EV develops a long-term investment strategy with their entrepreneurs. Their investment objective is to grow firms and to create a market leader in a new field. They focus on developing businesses active in industries including information technology, biotech, medtech and cleantech. They concentrate on various stages such as early to expansion-stage as well as spin-offs and restarts. Their geographic focus is pan-European. Specifically, their technology-sector investments are concentrated in Norway, Sweden, Finland, UK, Ireland, Germany, Switzerland, France, Italy and Portugal. Beyond these countries, they also consider taking a co-lead or a syndicate role. For their life sciences investments, they primarily target Switzerland, France and Germany. Four key investment criteria they consider before investment are hyper-growth market potential, world-class technology, capital efficiency and ambitious management team. EV's preferred role is to be lead investor or possibly co-lead. They also consider being syndicate partner on some occasions. EV's investment horizon is generally 10 years, with that timeframe extended for firms in hyper-growth stage. On average, their investments typically take five years to mature. The majority of their exits are through a listing in one of the main markets while many of the VC-backed firms are acquired.	Finance
The Wharton School of the University of Pennsylvania The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
JDRF T1D Fund JDRF T1D Fund Investment ManagersFinance T1D Fund invests in companies located across the globe. The firm focuses on health technology sector. It participates in early stage capital requirements.	Finance
Veralox Therapeutics, Inc. Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services for clinical stage company	Health Technology
I2o Therapeutics, Inc. I2o Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops injection pills for biological therapies	Health Technology
DiogenX SAS DiogenX SAS BiotechnologyHealth Technology Operates as preclinical stage biotech company, that engages in develops and research biologics therapeutics options for diabetic patients	Health Technology
Tech Health Experts Tech Health Experts Information Technology ServicesTechnology Services Provides technical support services	Technology Services
SAB Biotherapeutics, Inc. SAB Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in advancing a new class of immunotherapies	Health Technology